0001209191-20-064518.txt : 20201218
0001209191-20-064518.hdr.sgml : 20201218
20201218190217
ACCESSION NUMBER: 0001209191-20-064518
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201130
FILED AS OF DATE: 20201218
DATE AS OF CHANGE: 20201218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BJERKHOLT ERIC
CENTRAL INDEX KEY: 0001197350
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37345
FILM NUMBER: 201401971
MAIL ADDRESS:
STREET 1: 132 PURDURE AVENUE
CITY: KENGSINGTON
STATE: CA
ZIP: 94708
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001435049
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1600 FAIRVIEW AVE E.
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: 206-485-7051
MAIL ADDRESS:
STREET 1: 1600 FAIRVIEW AVE E.
CITY: SEATTLE
STATE: WA
ZIP: 98102
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH, INC.
DATE OF NAME CHANGE: 20111107
FORMER COMPANY:
FORMER CONFORMED NAME: ADURO BIOTECH
DATE OF NAME CHANGE: 20080514
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-11-30
0
0001435049
CHINOOK THERAPEUTICS, INC.
KDNY
0001197350
BJERKHOLT ERIC
C/O CHINOOK THERAPEUTICS, INC.
1600 FAIRVIEW AVE. E.
SEATTLE
WA
98102
0
1
0
0
Chief Financial Officer
Employee Stock Option (right to buy)
13.98
2020-11-30
4
A
0
144787
0.00
A
2030-11-29
Common Stock
144787
144787
D
Restricted Stock Units
2020-11-30
4
A
0
49243
0.00
A
Common Stock
49243
49243
D
The stock option vests as to 25% of the total shares on November 30, 2021, and thereafter vests as to 1/36 of the remaining shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Each restricted stock unit ("RSUs") represents a contingent right to receive one share of the Issuer's common stock.
The RSUs shall vest as to 33.33% of the total shares on November 30, 2021, and thereafter vests as to 33.33% of the total RSUs on November 30, 2022, and as to 33.33% of the total RSUs on November 30, 2023, subject to the provision of services to the Company on each vesting date.
/s/ Kirk Schumacher, Attorney-in-Fact
2020-12-18